Understanding the treatment benefits of novel antiviral agents for hepatitis C: quality of life, health utility, cost, and return to work
了解新型抗病毒药物治疗丙型肝炎的益处:生活质量、健康效用、成本和重返工作岗位
基本信息
- 批准号:346614
- 负责人:
- 金额:$ 34.25万
- 依托单位:
- 依托单位国家:加拿大
- 项目类别:Operating Grants
- 财政年份:2016
- 资助国家:加拿大
- 起止时间:2016-03-01 至 2019-03-01
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Hepatitis C virus (HCV) has been identified as having the highest health burden of any infectious disease pathogen. Direct-acting antiviral agents (DAAs) are new drugs that offer the promise of cure and substantially improved tolerability. Because of the
丙型肝炎病毒(HCV)已被确定为任何传染病病原体的健康负担最高。直接作用抗病毒药(DAAS)是新药,可提供治愈的希望并大大提高耐受性。因为
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wong William Wai Lun其他文献
Wong William Wai Lun的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wong William Wai Lun', 18)}}的其他基金
Towards establishing accurate estimates of national chronic hepatitis B prevalence and undiagnosed proportion in Canada
准确估计加拿大全国慢性乙型肝炎患病率和未确诊比例
- 批准号:
488763 - 财政年份:2023
- 资助金额:
$ 34.25万 - 项目类别:
Operating Grants
Developing policy models for sexually transmitted and blood-borne infection: integrating best evidence of effectiveness, safety, cost, and patient preferences
制定性传播和血源性感染的政策模型:整合有效性、安全性、成本和患者偏好的最佳证据
- 批准号:
499040 - 财政年份:2023
- 资助金额:
$ 34.25万 - 项目类别:
Salary Programs
Evaluating the impact of direct-acting antiviral treatment access policy on chronic hepatitis C prevalence and the undiagnosed proportion
评估直接抗病毒治疗获取政策对慢性丙型肝炎患病率和未确诊比例的影响
- 批准号:
475136 - 财政年份:2022
- 资助金额:
$ 34.25万 - 项目类别:
Operating Grants
Improvements in quality of life, health utility, cost, and return to work for lymphoma patients after chimeric antigen receptor T- cells therapy in a real-world setting
在现实环境中接受嵌合抗原受体 T 细胞治疗后,淋巴瘤患者的生活质量、健康效用、成本和重返工作得到改善
- 批准号:
456739 - 财政年份:2021
- 资助金额:
$ 34.25万 - 项目类别:
Operating Grants
Estimating chronic hepatitis B prevalence and the undiagnosed proportion in Canada using health administrative data
使用卫生行政数据估算加拿大慢性乙型肝炎的患病率和未确诊比例
- 批准号:
453432 - 财政年份:2021
- 资助金额:
$ 34.25万 - 项目类别:
Operating Grants
Understanding the treatment benefits of chimeric antigen receptor T-cells for lymphoma: quality of life, health utility, cost, and return to work
了解嵌合抗原受体 T 细胞治疗淋巴瘤的益处:生活质量、健康效用、成本和重返工作岗位
- 批准号:
438086 - 财政年份:2020
- 资助金额:
$ 34.25万 - 项目类别:
Operating Grants
Towards eliminating viral hepatitis - Addressing hepatitis B using a multidisciplinary approach
消除病毒性肝炎 - 使用多学科方法解决乙型肝炎
- 批准号:
414585 - 财政年份:2019
- 资助金额:
$ 34.25万 - 项目类别:
Operating Grants
Cross sectional and longitudinal measures of quality of life and utility among patients with chronic hepatitis C virus infection
慢性丙型肝炎病毒感染患者生活质量和效用的横断面和纵向测量
- 批准号:
310025 - 财政年份:2014
- 资助金额:
$ 34.25万 - 项目类别:
Operating Grants
相似海外基金
Identification of microRNA associated with the elimination of hepatitis C virus by direct-acting antiviral therapies
鉴定与直接作用抗病毒疗法消除丙型肝炎病毒相关的 microRNA
- 批准号:
18K15786 - 财政年份:2018
- 资助金额:
$ 34.25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Population-level impact of direct-acting antiviral (DAA) therapies for chronic hepatitis C on extrahepatic manifestations
直接作用抗病毒(DAA)治疗慢性丙型肝炎对肝外表现的人群影响
- 批准号:
375866 - 财政年份:2017
- 资助金额:
$ 34.25万 - 项目类别:
Fellowship Programs
Cross sectional and longitudinal measures of quality of life and utility among patients with chronic hepatitis C virus infection
慢性丙型肝炎病毒感染患者生活质量和效用的横断面和纵向测量
- 批准号:
310025 - 财政年份:2014
- 资助金额:
$ 34.25万 - 项目类别:
Operating Grants